{"id":187568,"date":"2025-11-18T18:38:08","date_gmt":"2025-11-18T18:38:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/187568\/"},"modified":"2025-11-18T18:38:08","modified_gmt":"2025-11-18T18:38:08","slug":"health-care-roundup-market-talk-11","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/187568\/","title":{"rendered":"Health Care Roundup: Market Talk"},"content":{"rendered":"<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1akm6h5-Paragraph e1e4oisd0\">The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.<\/p>\n<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1akm6h5-Paragraph e1e4oisd0\">1602 ET \u2013 The market for Nuvalent\u2019s new neladalkib treatment for lung cancer may reach as much as $2 billion, Cantor Fitzgerald analysts Josh Schimmer and Imogen Mansfield say in a note. Results from Nuvalent\u2019s Phase 1\/2 trial suggest the drug is poised to upend lorlatinib as the premier ALK inhibitor on the market, noting that the company had to halt enrollment in the trial because it was growing too expensive. Unlike Pfizer\u2019s lorlatinib, \u201cNUVL offers doctors &amp; patients both efficacy and tolerability.\u201d Nuvalent shares are up 12% to $108.48. (<a data-type=\"link\" href=\"https:\/\/www.wsj.com\/articles\/mailto:elias.schisgall@wsj.com\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">elias.schisgall@wsj.com<\/a>)<\/p>\n<p class=\"css-16aepit e1jdulti0\">Copyright \u00a92025 Dow Jones &amp; Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,&hellip;\n","protected":false},"author":2,"featured_media":187569,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[95433,95431,105218,50843,97416,85833,41573,110,41570,13782,41565,7266,18,1015,85543,41571,2220,3334,135,475,474,82485,82483,19,41586,17,3544,105219,3865,66836,82490,82488,1474,12490,82482,2900,9436,44285,7981,82487,17917,172,82486,82491,827,26243,8952,41580],"class_list":{"0":"post-187568","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-analysts-comments","9":"tag-analysts-comments-recommendations","10":"tag-biological-therapy","11":"tag-biopharmaceuticals","12":"tag-biotechnology-services","13":"tag-ce-exclusion-filter","14":"tag-ce-industry-news-filter","15":"tag-cancer","16":"tag-content-types","17":"tag-corporate","18":"tag-corporate-industrial-news","19":"tag-development","20":"tag-eire","21":"tag-europe","22":"tag-european-union-countries","23":"tag-factiva-filters","24":"tag-france","25":"tag-general-news","26":"tag-health","27":"tag-health-care","28":"tag-healthcare","29":"tag-healthcare-provision","30":"tag-healthcare-life-sciences","31":"tag-ie","32":"tag-industrial-news","33":"tag-ireland","34":"tag-life-sciences","35":"tag-linkendrnrealtime-linkedarticle-dnco20251117008331","36":"tag-medical-conditions","37":"tag-mediterranean-countries","38":"tag-new-product","39":"tag-new-product-service-testing","40":"tag-new-products","41":"tag-new-products-services","42":"tag-newsplus","43":"tag-pharmaceuticals","44":"tag-political","45":"tag-political-general-news","46":"tag-products","47":"tag-products-services","48":"tag-recommendations","49":"tag-research","50":"tag-research-development","51":"tag-service-testing","52":"tag-services","53":"tag-synd","54":"tag-western-europe","55":"tag-wsj-pro-wsj-com"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/187568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=187568"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/187568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/187569"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=187568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=187568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=187568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}